BCIQ Profiles

Company Profile Report
0607 Adu stocks
BioCentury & Getty Images

Finance

Aducanumab approval lifts shares of biotechs with Alzheimer’s programs

Biogen and Lilly together gain $36B in market cap

Biogen and Lilly together gain $36B in market cap.

Jun 7, 2021 | 11:30 PM GMT

FDA’s willingness to approve Biogen’s aducanumab based on a surrogate endpoint rather than clinical benefit has created the perception that other biopharmas with Alzheimer’s programs may have a

Read the full 650 word article

How to gain access

Continue reading with a
two-week free trial.